A randomized, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome: PALISADE - 1 year open label extension
Event:
ESC Congress 2025
Topic:
Cardiovascular Disease in Primary Care
Session:
Cardiovascular disease in primary care